Skip to main content
Log in

A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET)

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Background & Aims: The COMET trial was a prospective, double-blind, randomised trial comparing carvedilol, a comprehensive adrenergic receptor antagonist, with metoprolol, a beta-1-selective agent in patients with heart failure and left ventricular systolic dysfunction. The trial showed a reduction in mortality with carvedilol that was consistent across subgroups. The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics.

Methods: A descriptive report using data entered in the COMET study data-base.

Results: The characteristics of the population studied were similar to those reported in previous trials of beta-blockers. Almost all patients were receiving diuretics and ACE inhibitors with few patients taking angiotensin receptor blockers. As expected, older patients had more co-morbidity. Older patients and women reported worse symptoms and poorer well-being despite similar ventricular dimensions and systolic dysfunction. NT-proBNP was higher in patients with more severe symptoms and older patients but not in women, although differences in NT-proBNP may have been confounded by differences in renal function.

Conclusion: Age and gender, as well as the severity of cardiac dysfunction, appear to have an important effect on the severity of heart failure symptoms and patient ‘well-being’. This could have important implications for the relationship between symptoms and prognosis and therefore the way in which patients are selected for clinical trials and the goals of treatment. This will be the subject of further analyses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cleland JGF, Clark AL. Delivering the cumulative benefits of triple therapy for heart failure. Too many cooks will spoil the broth. JACC 2003;42:1226–1233.

    Google Scholar 

  2. Coletta AP, Cleland JGF, Freemantle N, Loh H, Memon A, Clark AL. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Failure 2003.

  3. Cleland JGF, McMurray JJF, Cowburn PJ. Heart Failure: A Systematic Approach for Clinical Practice, 1st ed. London: Science Press, 1997.

    Google Scholar 

  4. Poole-Wilson PA, Cleland JGF, Hanrath P, et al., on behalf of the COMET Study Investigators. Rationale and design of the carvedilol or metoprolol european trial in patients with chronic heart failure; the COMET trial. Eur J Heart Fail 2002;4(3):321–329.

    Article  PubMed  CAS  Google Scholar 

  5. Poole-Wilson PA, Swedberg K, Cleland JGF, et al., for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003;362:7–13.

    Article  PubMed  CAS  Google Scholar 

  6. Cleland JGF, Bristow M, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J 1996;17:1629–1639.

    PubMed  CAS  Google Scholar 

  7. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. Am Heart J 2001;141:899–907.

    Article  PubMed  CAS  Google Scholar 

  8. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. Am Soc Nephrol 2000;11:A0828. Ref Type: Abstract

    Google Scholar 

  9. CIBIS-II Investigators and Committee. The Cardiac insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9–13.

    Article  Google Scholar 

  10. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;333:2001–2007.

    Google Scholar 

  11. Packer M, Bristow MR, Cohn JN, et al., for the US carvedilol study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996;334:1349–1355.

    Article  PubMed  CAS  Google Scholar 

  12. Cleland JGF, Swedberg K, Follath F, et al., for the study group on diagnosis of the working group on Heart Failure of the European Society of Cardiology, Freemantle N, Eastaugh J, Mason J. The EuroHeart failure survey programme: Survey on the quality of care among patients with Heart Failure in Europe. Part 1: Patient Characteristics and Diagnosis. Eur Heart J 2003;24:422–463.

    Google Scholar 

  13. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JGF. Diastolic heart failure-neglected or misdiagnosed? J Am Coll Cardiol 2002;39(1):138–141.

    Article  PubMed  Google Scholar 

  14. Caruana L, Petrie MC, Davie AP, McMurray JV. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from “diastolic heart failure” or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215–218.

    Article  PubMed  CAS  Google Scholar 

  15. Carson P, Johnson G, Fletcher R, Cohn J. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): Baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol 1996;27:642–649.

    Article  PubMed  CAS  Google Scholar 

  16. Cohn JN, Archibald DG, Francis GS, et al. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: Influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 1987;75:IV-49–IV-54.

    CAS  Google Scholar 

  17. Swedberg K, Idanpaan Heikkila U, Remes J, for the CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 1987;316:1429–1435.

    Article  Google Scholar 

  18. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786–2792.

    Article  PubMed  CAS  Google Scholar 

  19. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-Terminal Pro-Brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921–1929.

    PubMed  CAS  Google Scholar 

  20. Remme WJ, Cleland JGF, et al., European Society of Cardiology. Guidelines for the management of heart failure. Eur Heart J 1997;18:736–753.

    CAS  Google Scholar 

  21. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341(10):709–717.

    Article  PubMed  CAS  Google Scholar 

  22. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998;19:696–710.

    Article  PubMed  CAS  Google Scholar 

  23. Dutka DP, Olivotto I, Ward S, Oakley CM, Impallomeni M, Cleland JGF. Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic function. Am J Cardiol 1996;77:1197–1201.

    Article  PubMed  CAS  Google Scholar 

  24. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829–833.

    Article  PubMed  CAS  Google Scholar 

  25. Dutka DP, Olivotto I, Ward S, et al. Plasma neuroendocrine activity in very elderly subjects and patients with and without heart failure. Eur Heart J 1995;16:1223–1230.

    PubMed  CAS  Google Scholar 

  26. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. New Engl J Med 2002;347:1403–1411.

    Article  PubMed  CAS  Google Scholar 

  27. Os I, Bratland B, Dahlof B, et al. Female sex as an important determinant of lisinopril-induced cough. Lancet 1992;339:303–310.

    Article  Google Scholar 

  28. Goodwin JF, Oakley CM. The cardiomyopathies. Br Heart J 1972;34:545–552.

    PubMed  CAS  Google Scholar 

  29. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996;93:841–842.

    PubMed  CAS  Google Scholar 

  30. Cleland JGF, Alamgir F, Nikitin N, Clark A, Norell M. What is the optimal medical management of ischaemic heart failure? Prog Cardiovasc Dis 2001;43(5):433–455.

    Article  PubMed  CAS  Google Scholar 

  31. Cleland JGF. Is aspirin ‘The Weakest Link’ in cardiovascular prophylaxis. The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 2002;44:275–292.

    Article  PubMed  CAS  Google Scholar 

  32. Cleland JGF, Freemantle N, Ball SG, et al. The heart failure revascularization trial (HEART): Rationale design and methodolog. Eur J Heart Fail 2003;5(3):295–303.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cleland, J.G., Goode, K., Erhardt, L. et al. A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovasc Drugs Ther 18, 139–152 (2004). https://doi.org/10.1023/B:CARD.0000029032.46744.56

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CARD.0000029032.46744.56

Navigation